SCHEDULE: Vivo Opportunity Fund Discloses 4.2% Stake in Soleno Therapeutics

Vivo Opportunity Fund Holdings, L.P. and its affiliates reported a 4.2% beneficial ownership stake in Soleno Therapeutics, Inc. common stock.

Summary

• Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC, collectively beneficially own 2,251,160 shares of Soleno Therapeutics, Inc. common stock.
• This ownership represents 4.2% of the total class of securities outstanding.
• Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC, collectively beneficially own 27,043 shares, representing 0.1% of the class.
• The percentage of class was calculated based on 53,710,025 shares of Soleno Therapeutics, Inc. common stock outstanding as of October 31, 2025.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This filing is a factual disclosure of beneficial ownership and does not contain explicit positive or negative operational or financial news. It is an amendment to a previous filing, indicating a change in reported ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Provides transparency to shareholders regarding significant institutional holdings and changes in such holdings.
• Informs the market about the passive investment intent of Vivo Opportunity Fund Holdings, L.P. and its affiliates.

Key Dates

Keywords

Soleno Therapeutics, Vivo Opportunity Fund, Schedule 13G, beneficial ownership, institutional investor, common stock